Lon Smith

3.9k total citations · 1 hit paper
35 papers, 2.5k citations indexed

About

Lon Smith is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lon Smith has authored 35 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lon Smith's work include Cancer Treatment and Pharmacology (7 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Lon Smith is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Lon Smith collaborates with scholars based in United States, France and Japan. Lon Smith's co-authors include Daniel D. Von Hoff, Manuel Hidalgo, John G. Kuhn, John R. Eckardt, Howard A. Burris, Geoffrey R. Weiss, Mitesh J. Borad, Tina E. Wood, Daniel A. Laheru and Amita Patnaik and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Lon Smith

35 papers receiving 2.5k citations

Hit Papers

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Pa... 2011 2026 2016 2021 2011 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
    2011 823 citations Daniel D. Von Hoff, Mitesh J. Borad et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lon Smith United States 17 1.8k 1.1k 452 429 254 35 2.5k
Nicholas W. Choong United States 19 1.8k 1.0× 1.7k 1.5× 221 0.5× 595 1.4× 277 1.1× 48 2.8k
Heike Richly Germany 20 1.2k 0.6× 1.1k 0.9× 380 0.8× 736 1.7× 181 0.7× 56 2.4k
Sreenivasa Nattam United States 20 1.9k 1.0× 760 0.7× 378 0.8× 1.0k 2.4× 288 1.1× 42 2.6k
Marta Guix Spain 17 1.4k 0.8× 1.1k 1.0× 599 1.3× 714 1.7× 348 1.4× 43 2.5k
Michael Millward Australia 25 1.7k 0.9× 1.1k 1.0× 331 0.7× 1.1k 2.7× 331 1.3× 43 2.9k
Vinod Ganju Australia 24 2.0k 1.1× 655 0.6× 447 1.0× 906 2.1× 323 1.3× 94 2.7k
S. Kakolyris Greece 32 1.9k 1.0× 1.0k 0.9× 816 1.8× 925 2.2× 254 1.0× 90 3.0k
Lainie P. Martin United States 29 1.7k 0.9× 1.2k 1.0× 366 0.8× 414 1.0× 278 1.1× 100 3.2k
Archie Tse United States 23 2.0k 1.1× 1.4k 1.3× 311 0.7× 947 2.2× 349 1.4× 59 3.3k
Stephen Leong United States 23 1.1k 0.6× 842 0.7× 606 1.3× 471 1.1× 350 1.4× 73 2.3k

Countries citing papers authored by Lon Smith

Since Specialization
Citations

This map shows the geographic impact of Lon Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lon Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lon Smith more than expected).

Fields of papers citing papers by Lon Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lon Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lon Smith. The network helps show where Lon Smith may publish in the future.

Co-authorship network of co-authors of Lon Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Lon Smith. A scholar is included among the top collaborators of Lon Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lon Smith. Lon Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Patnaik, Amita, Erika Hamilton, Drew Rasco, et al.. (2022). A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors. Cancers. 14(20). 4996–4996. 1 indexed citations
2.
3.
Shimizu, Toshio, Patricia LoRusso, K. Papadopoulos, et al.. (2014). Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(19). 5032–5040. 67 indexed citations
4.
Rangel, Letícia Batista Azevedo, et al.. (2014). Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer. Breast Cancer Research and Treatment. 148(3). 571–580. 4 indexed citations
5.
O’Reilly, Eileen M., Lon Smith, Johanna C. Bendell, et al.. (2014). Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 32(3_suppl). 220–220. 9 indexed citations
6.
Infante, Jeffrey R., Kyriakos P. Papadopoulos, Johanna C. Bendell, et al.. (2013). A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. European Journal of Cancer. 49(9). 2077–2085. 64 indexed citations
7.
Shimizu, Toshio, Anthony W. Tolcher, Kyriakos P. Papadopoulos, et al.. (2012). The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer. Clinical Cancer Research. 18(8). 2316–2325. 352 indexed citations
8.
Kurzrock, Razelle, Akash Patnaik, Sidney W. Fu, et al.. (2011). Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).. Journal of Clinical Oncology. 29(15_suppl). 3085–3085. 26 indexed citations
9.
Chisholm, Gary B., et al.. (2008). ER alpha genotypes and breast cancer recurrence. Journal of Clinical Oncology. 26(15_suppl). 501–501. 5 indexed citations
10.
Rodón, Jordi, Mitchell Garrison, Lisa A. Hammond, et al.. (2008). Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemotherapy and Pharmacology. 62(5). 911–919. 25 indexed citations
11.
Smith, Lon, Ronald Drengler, Tina E. Wood, et al.. (2008). SPARC and CA19–9 as biomarkers in patients with advanced pancreatic cancer treated with nab paclitaxel plus gemcitabine. Journal of Clinical Oncology. 26(15_suppl). 15592–15592. 2 indexed citations
12.
Smith, Lon, Gary B. Chisholm, Ronald Drengler, et al.. (2006). Relationship between CYP2D6 and estrogen receptor alpha polymorphisms on tamoxifen metabolism in adjuvant breast cancer treatment. Journal of Clinical Oncology. 24(18_suppl). 505–505. 7 indexed citations
13.
Smith, Lon, Gary B. Chisholm, Ronald Drengler, et al.. (2005). Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. Breast Cancer Research and Treatment. 95(1). 13–16. 19 indexed citations
14.
Hidalgo, Manuel, Cheryl Aylesworth, Lisa A. Hammond, et al.. (2001). Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel. Journal of Clinical Oncology. 19(9). 2493–2503. 33 indexed citations
15.
Rowinsky, Eric K., Rachel Humphrey, Lisa A. Hammond, et al.. (2000). Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies. Journal of Clinical Oncology. 18(1). 178–178. 72 indexed citations
16.
Eckhardt, S. Gail, Jinee Rizzo, Kevin Sweeney, et al.. (1999). Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 17(4). 1095–1095. 55 indexed citations
17.
Peacock, N. W., H.A. Burris, Véronique Dièras, et al.. (1998). A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. Investigational New Drugs. 16(1). 37–43. 5 indexed citations
18.
Rothenberg, Mace L., John R. Eckardt, John G. Kuhn, et al.. (1996). Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.. Journal of Clinical Oncology. 14(4). 1128–1135. 305 indexed citations
19.
Weiss, Geoffrey R., John G. Kuhn, Jinee Rizzo, et al.. (1995). A Phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 35(5). 397–402. 12 indexed citations
20.
Burris, Howard A., Ahmad Awada, John G. Kuhn, et al.. (1994). Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anti-Cancer Drugs. 5(4). 394–402. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicholas W. Choong Breakdown of academic impact, for papers by Heike Richly Breakdown of academic impact, for papers by Sreenivasa Nattam Breakdown of academic impact, for papers by Marta Guix Breakdown of academic impact, for papers by Michael Millward Breakdown of academic impact, for papers by Vinod Ganju Breakdown of academic impact, for papers by S. Kakolyris Breakdown of academic impact, for papers by Lainie P. Martin Breakdown of academic impact, for papers by Archie Tse Breakdown of academic impact, for papers by Stephen Leong
Rankless by CCL
2026